サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1422888

微小残存病変（MRD）検査市場：技術、用途、エンドユーザー、地域別、2024年～2032年

Minimal Residual Disease Testing Market by Technology (Flow Cytometry, Polymerase Chain Reaction, Next Generation Sequencing, and Others), Application, End User, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 141 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
微小残存病変（MRD）検査市場：技術、用途、エンドユーザー、地域別、2024年～2032年
出版日: 2024年01月30日
発行: IMARC
ページ情報: 英文 141 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の微小残存病変（MRD）検査市場規模は、2023年に21億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて10.21%の成長率（CAGR）を示し、2032年までに51億米ドルに達すると予測しています。ヘルスケア産業の著しい成長、広範な研究開発（R&D）活動、急速な技術進歩が市場を牽引する主な要因です。

微小残存病変（MRD）検査は、がん治療後に患者の体内に残存する可能性のある少量のがん細胞を検出・監視するために用いられる医療検査です。MRD検査は、白血病、リンパ腫、多発性骨髄腫、一部の固形がんなど、さまざまな種類のがんの検査に広く用いられています。MRD検査では、サイトメトリー、ポリメラーゼ連鎖反応（PCR）、次世代シークエンシング（NGS）など、感度の高い方法が用いられます。MRD検査は、がん患者をモニタリングし、医師が十分な情報を得た上で治療方針を決定するための重要な医療検査です。MRD検査は、疾患の再発を早期に発見し、治療反応をより正確に評価し、患者を特定し、患者の転帰を改善し、カスタマイズされた治療計画を強化することによって、個別化された治療計画を導くのに役立ちます。

微小残存病変（MRD）検査の市場動向：

世界中でがんの有病率が増加していることが、市場成長を促進する主な要因の1つです。MRD検査は、残存がん細胞を検出するために広く使用されている高感度技術であり、疾患の再発を早期に示唆し、個別化された治療計画の指針となります。これに伴い、造血組織または免疫系の細胞から始まる血液がんにおいて、診断およびモニタリングツールとしてMRD検査が広く採用されていることが、市場の成長を後押ししています。さらに、カスタマイズされた治療計画やモニタリングを可能にする個別化医療に対する消費者の嗜好の変化が、もう一つの成長促進要因として作用しています。これとは別に、人工知能（AI）をMRD検査に統合することで、パターンの特定、再発の可能性の予測、診断の正確性と有効性の向上、臨床医が患者のケアについてより多くの情報に基づいた意思決定を行うのに役立ち、市場成長に弾みをつけています。さらに、デオキシリボ核酸（DNA）またはリボ核酸（RNA）の塩基配列を決定し、疾患に関連する遺伝的変異を研究するためのNGS技術の採用が増加していることも、市場に明るい展望をもたらしています。さらに、体内でがんを引き起こす可能性のある発がん性物質の存在を特定することの重要性に対する人々の意識の高まりが、市場の成長を後押ししています。ヘルスケア産業の著しい成長、広範な研究開発（R&D）活動、MRD検査プログラム分野への投資の増加など、その他の要因も市場成長を促進すると予想されます。

本レポートで扱う主な質問

  • 世界の微小残存病変（MRD）検査市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
  • 世界の微小残存病変（MRD）検査市場の市場促進要因、抑制要因、機会は何か？
  • 促進要因、抑制要因、機会が世界の微小残存病変（MRD）検査市場に与える影響は？
  • 主要な地域市場は？
  • 最も魅力的な微小残存病変（MRD）検査市場はどの国か？
  • 技術別の市場内訳は？
  • 微小残存病変（MRD）検査市場で最も魅力的な技術はどれか？
  • 用途別の市場内訳は？
  • 微小残存病変（MRD）検査市場で最も魅力的な用途はどれか？
  • エンドユーザー別の市場内訳は？
  • 微小残存病変（MRD）検査市場で最も魅力的なエンドユーザーはどこか？
  • 世界の微小残存病変（MRD）検査市場の競合構造は？
  • 微小残存病変（MRD）検査の世界市場における主要プレイヤー/企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 微小残存病変（MRD）検査の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：技術別

  • フローサイトメトリー
    • 市場動向
    • 市場予測
  • ポリメラーゼ連鎖反応（PCR）
    • 市場動向
    • 市場予測
  • 次世代シーケンサー（NGS）
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：用途別

  • 血液悪性腫瘍
    • 市場動向
    • 主要セグメント
      • 白血病
      • リンパ腫
    • 市場予測
  • 固形がん
    • 市場動向
    • 市場予測

第8章 市場内訳：エンドユーザー別

  • 病院・専門クリニック
    • 市場動向
    • 市場予測
  • 診断ラボ
    • 市場動向
    • 市場予測
  • 学術研究機関
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 促進要因、抑制要因、機会

  • 市場概要
  • 促進要因
  • 抑制要因
  • 機会

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Adaptive Biotechnologies Corporation
    • Arup Laboratories Inc.
    • Bio-Rad Laboratories Inc.
    • Guardant Health
    • Invivoscribe Inc.
    • Natera Inc.
    • NeoGenomics Laboratories Inc.
    • Sysmex Corporation
図表

List of Figures

  • Figure 1: Global: Minimal Residual Disease Testing Market: Major Drivers and Challenges
  • Figure 2: Global: Minimal Residual Disease Testing Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Minimal Residual Disease Testing Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Minimal Residual Disease Testing Market: Breakup by Technology (in %), 2023
  • Figure 5: Global: Minimal Residual Disease Testing Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Minimal Residual Disease Testing Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Minimal Residual Disease Testing Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Minimal Residual Disease Testing (Flow Cytometry) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Minimal Residual Disease Testing (Flow Cytometry) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Minimal Residual Disease Testing (Polymerase Chain Reaction (PCR)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Minimal Residual Disease Testing (Polymerase Chain Reaction (PCR)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Minimal Residual Disease Testing (Next Generation Sequencing (NGS)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Minimal Residual Disease Testing (Next Generation Sequencing (NGS)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Minimal Residual Disease Testing (Other Technologies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Minimal Residual Disease Testing (Other Technologies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Minimal Residual Disease Testing (Hematological Malignancy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Minimal Residual Disease Testing (Hematological Malignancy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Minimal Residual Disease Testing (Solid Tumors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Minimal Residual Disease Testing (Solid Tumors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Minimal Residual Disease Testing (Hospitals and Speciality Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Minimal Residual Disease Testing (Hospitals and Speciality Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Minimal Residual Disease Testing (Diagnostic Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Minimal Residual Disease Testing (Diagnostic Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Minimal Residual Disease Testing (Academic and Research Institutes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Minimal Residual Disease Testing (Academic and Research Institutes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Minimal Residual Disease Testing (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Minimal Residual Disease Testing (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia-Pacific: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia-Pacific: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Minimal Residual Disease Testing Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Minimal Residual Disease Testing Market: Breakup by Country (in %), 2023
  • Figure 76: Middle East and Africa: Minimal Residual Disease Testing Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Global: Minimal Residual Disease Testing Industry: Drivers, Restraints, and Opportunities
  • Figure 78: Global: Minimal Residual Disease Testing Industry: Value Chain Analysis
  • Figure 79: Global: Minimal Residual Disease Testing Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Minimal Residual Disease Testing Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Technology (in Million US$), 2024-2032
  • Table 3: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 4: Global: Minimal Residual Disease Testing Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Minimal Residual Disease Testing Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Minimal Residual Disease Testing Market: Competitive Structure
  • Table 7: Global: Minimal Residual Disease Testing Market: Key Players
目次
Product Code: SR112024A7248

Abstract

The global minimal residual disease (MRD) testing market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.1 Billion by 2032, exhibiting a growth rate (CAGR) of 10.21% during 2024-2032. Significant growth in the healthcare industry, extensive research and development (R&D) activities and rapid technological advancements represent some of the key factors driving the market.

Minimal residual disease (MRD) testing is a medical test used to detect and monitor small amounts of cancer cells that may remain in a patient's body after undergoing cancer treatment. It is widely used to test a variety of different types of cancer, such as leukemia, lymphoma, multiple myeloma, and some solid tumors. MRD testing uses highly sensitive methods, including cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS). It is an important medical test for monitoring cancer patients and helping doctors to make more informed treatment decisions. MRD testing helps in the early detection of disease recurrence, providing a more accurate assessment of treatment response and guiding personalized treatment planning by identifying patients, improving patient outcomes, and enhancing customized treatment planning.

Minimal Residual Disease (MRD) Testing Market Trends:

The increasing prevalence of cancer across the globe is one of the key factors driving the market growth. MRD testing is a highly sensitive technique that is widely used to detect residual cancer cells, which helps in an early indication of disease recurrence and helps guide personalized treatment planning. In line with this, the widespread adoption of MRD testing as a diagnostic and monitoring tool in hematological cancers that begin in blood-forming tissues or the cell of the immune system is favoring the market growth. Moreover, the shifting consumer preference toward personalized medicine that allows customized treatment planning and monitoring are acting as another growth-inducing factor. Apart from this, the integration of artificial intelligence (AI) with MRD testing that helps to identify patterns, predict the likelihood of recurrence, improve the accuracy and effectiveness of diagnosis, and help clinicians to make more informed decisions about patient care, is providing an impetus to the market growth. Additionally, the increasing adoption of NGS technology to determine the sequence of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) to study the genetic variations associated with the disease is creating a positive outlook for the market. Furthermore, growing awareness among people about the importance of identifying the presence of carcinogenic substances that can cause cancer in the body is propelling the market growth. Other factors, including significant growth in the healthcare industry, extensive research and development (R&D) activities, and increasing investments in the field of MRD testing programs, are anticipated to drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global minimal residual disease (MRD) testing market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on technology, application, and end user.

Technology Insights:

Flow Cytometry

Polymerase Chain Reaction (PCR)

Next Generation Sequencing (NGS)

Others

The report has provided a detailed breakup and analysis of the minimal residual disease (MRD) testing market based on the technology. This includes flow cytometry, polymerase chain reaction (PCR), next generation sequencing (NGS) and others. According to the report, polymerase chain reaction (PCR) represented the largest segment.

Application Insights:

Hematological Malignancy

Leukemia

Lymphoma

Solid Tumors

A detailed breakup and analysis of the minimal residual disease (MRD) testing market based on the application has also been provided in the report. This includes hematological malignancy (leukemia and lymphoma) and solid tumors. According to the report, hematological malignancy (leukemia and lymphoma) accounted for the largest market share.

End User Insights:

Hospitals and Speciality Clinics

Diagnostic Laboratories

Academic and Research Institutes

Others

The report has provided a detailed breakup and analysis of the minimal residual disease (MRD) testing market based on the end user. This includes hospitals and speciality clinics, diagnostic laboratories, academic and research institutes, and others. According to the report, hospitals and speciality clinics represented the largest segment.

Regional Insights:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for minimal residual disease (MRD) testing. Some of the factors driving the North America minimal residual disease (MRD) testing market included the increasing prevalence of cancer, significant growth in the healthcare industry, and extensive research and development (R&D) activities.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global minimal residual disease (MRD) testing market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Adaptive Biotechnologies Corporation, Arup Laboratories Inc., Bio-Rad Laboratories Inc., Guardant Health, Invivoscribe Inc., Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, etc.

Key Questions Answered in This Report:

  • How has the global minimal residual disease (MRD) testing market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global minimal residual disease (MRD) testing market?
  • What is the impact of each driver, restraint, and opportunity on the global minimal residual disease (MRD) testing market?
  • What are the key regional markets?
  • Which countries represent the most attractive minimal residual disease (MRD) testing market?
  • What is the breakup of the market based on technology?
  • Which is the most attractive technology in the minimal residual disease (MRD) testing market?
  • What is the breakup of the market based on the application?
  • Which is the most attractive application in the minimal residual disease (MRD) testing market?
  • What is the breakup of the market based on the end user?
  • Which is the most attractive end user in the minimal residual disease (MRD) testing market?
  • What is the competitive structure of the global minimal residual disease (MRD) testing market?
  • Who are the key players/companies in the global minimal residual disease (MRD) testing market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Minimal Residual Disease (MRD) Testing Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 Flow Cytometry
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Polymerase Chain Reaction (PCR)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Next Generation Sequencing (NGS)
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Hematological Malignancy
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Leukemia
      • 7.1.2.2 Lymphoma
    • 7.1.3 Market Forecast
  • 7.2 Solid Tumors
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals and Speciality Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Diagnostic Laboratories
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Academic and Research Institutes
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Adaptive Biotechnologies Corporation
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Arup Laboratories Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 SWOT Analysis
    • 14.3.3 Bio-Rad Laboratories Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Guardant Health
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 Invivoscribe Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Natera Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
    • 14.3.7 NeoGenomics Laboratories Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
    • 14.3.8 Sysmex Corporation
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis